DMK PHARMACEUTICALS Corp financial data

Symbol
DMKPQ on OTC
Industry
Pharmaceutical Preparations
Location
11682 El Camino Real, Suite 300, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Adamis Pharmaceuticals Corp (to 9/1/2023), CELLEGY PHARMACEUTICALS INC (to 4/3/2009)
Latest financial report
10-Q - Q3 2023 - Nov 14, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 53.3 % -73.8%
Quick Ratio 6.12 % +33.9%
Debt-to-equity -219 % -341%
Return On Assets -264 % -104%
Operating Margin -719 % +62.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.1M shares -93.3%
Common Stock, Shares, Outstanding 10.1M shares -93.3%
Entity Public Float 74.4M USD -54.3%
Common Stock, Value, Issued 1.01K USD -93.3%
Weighted Average Number of Shares Outstanding, Basic 7.07M shares +230%
Weighted Average Number of Shares Outstanding, Diluted 7.07M shares +230%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 3.53M USD +138%
Research and Development Expense 7.47M USD -43.6%
Operating Income (Loss) -25.3M USD +11.7%
Nonoperating Income (Expense) 4.18M USD +328%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.01M USD +11.5%
Net Income (Loss) Attributable to Parent -22.2M USD +30.4%
Earnings Per Share, Basic 2.2 USD/shares +90.2%
Earnings Per Share, Diluted 2.2 USD/shares +90.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.66M USD +175%
Inventory, Net 663K USD -39.3%
Other Assets, Current 67.2K USD
Assets, Current 7.87M USD -22%
Property, Plant and Equipment, Net 1.08M USD -32.6%
Operating Lease, Right-of-Use Asset 146K USD -70%
Other Assets, Noncurrent 9.67K USD -81.5%
Assets 8.96M USD -26.2%
Accounts Payable, Current 9.97M USD +88.3%
Accrued Liabilities, Current 2.32M USD +73.2%
Liabilities, Current 13.5M USD +51.7%
Operating Lease, Liability, Noncurrent 63.2K USD -85.4%
Liabilities 13.9M USD +52.4%
Retained Earnings (Accumulated Deficit) -323M USD -7.38%
Stockholders' Equity Attributable to Parent -5.29M USD -286%
Liabilities and Equity 8.96M USD -26.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.55M USD +77.8%
Net Cash Provided by (Used in) Financing Activities 2.72M USD
Net Cash Provided by (Used in) Investing Activities 842K USD -45.1%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 10.1M shares -93.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.02M USD
Deferred Tax Assets, Valuation Allowance 60.2M USD +11%
Deferred Tax Assets, Gross 62.2M USD +10.5%
Operating Lease, Liability 343K USD -50.5%
Depreciation 636K USD -56.9%
Payments to Acquire Property, Plant, and Equipment 26.9K USD -93.4%
Lessee, Operating Lease, Liability, to be Paid 349K USD -51.5%
Operating Lease, Liability, Current 63.2K USD -82.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 349K USD -5.82%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.8K USD -75.6%
Deferred Tax Assets, Operating Loss Carryforwards 51.5M USD +8.57%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Operating Lease, Payments 371K USD +3.06%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.95M USD -3.32%
Share-based Payment Arrangement, Expense -249K USD -160%
Interest Expense 29.5K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares